



Medicaid and Health Wave  
900 SW Jackson Street  
Rm. 900-N  
Topeka, KS 66612  
Phone: 785-296-3981  
Fax: 785-296-4813  
[www.khpa.ks.gov](http://www.khpa.ks.gov)

**Preferred Drug List Committee  
Meeting Agenda, Open Session  
December 16, 2009, 10:00 a.m.**

**Meeting Location:**

HP Enterprise Services ~ Capital and Cedar Crest Rooms  
6700 SW Topeka Blvd, Bldg. 283 J, Topeka, Kansas 66619

**Members:**

Michael Burke, M.D, Ph.D., Chair  
Kristin Fink, Pharm.D.  
Robert Haneke, Pharm.D.  
Glenn Harte, Pharm.D.  
Kenneth Mishler, Pharm.D.  
Brenda Schewe, M.D.  
Matthew Schlotterback, M.D.  
Donna Sweet, M.D.  
Dennis D. Tietze, M.D.

**KHPA:**

LeAnn Bell, Pharm.D.  
Aimee Grubb, Recorder  
Shelly Liby  
Margaret Smith, M.D.

**HP Enterprise Services:**

Karen Kluczykowski, R.Ph.  
Lisa Todd, R.Ph.

- I. Welcome and Announcements
- II. Review and Approval of June 3, 2009 Meeting Minutes
- III. Update on Budget and DERP
- IV. Long Acting Insulins – New Review
  - A. \*Public Comment
  - B. Committee Discussion and Recommendation
- V. Targeted Immune Modulators (Biologics) – New Review
  - A. \*Public Comment
  - B. Committee Discussion and Recommendation

Continued on back

- VI. DPP-4 Inhibitors (Gliptins) – New Review
  - A. \*Public Comment
  - B. Committee Discussion and Recommendation
  
- VII. Angiotensin Receptor Blocker/Calcium Channel Blocker (ARB/CCB) Combos – New Review
  - A. \*Public Comment
  - B. Committee Discussion and Recommendation
  
- VIII. HMG-CoA Reductase Inhibitors (Statins) – Re-Review
  - A. \*Public Comment
  - B. Committee Discussion and Recommendation
  
- IX. Proton Pump Inhibitors – Re-Review
  - A. \*Public Comment
  - B. Committee Discussion and Recommendation
  
- X. Drugs for Insomnia – Re-Review
  - C. \*Public Comment
  - D. Committee Discussion and Recommendation
  
- XI. Adjourn

**Lunch for PDL Committee Members after meeting adjourned**  
**NEXT MEETING: June 16, 2010**

\*Public Comment is limited to five minutes per product; additional time will be allowed at the Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.